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Abstract
Introduction: Regulated neurotransmitter actions in the mammalian central nervous system determine brain
function and control peripheral organs and behavior. Although drug-seeking behaviors, including alcohol
consumption, depend on central neurotransmission, modification of neurotransmitter actions in specific brain
nuclei remains challenging. Herein, we report a novel approach for neurotransmission modification in vivo by
transplantation of stem cells engineered to take up the neurotransmitter dopamine (DA) efficiently through the
action of the human dopamine transporter (hDAT). As a functional test in mice, we used voluntary alcohol
consumption, which is known to release DA in nucleus accumbens (NAC), an event hypothesized to help maintain
drug-seeking behavior. We reasoned that reducing extracellular DA levels, by engrafting into NAC DA-sequestering
stem cells expressing hDAT, would alter alcohol intake.
Methods: We have generated a neural stem cell line stably expressing the hDAT. Uptake kinetics of DA were
determined to select a clone for transplantation. These genetically modified stem cells (or cells transfected with a
construct lacking the hDAT sequence) were transplanted bilaterally into the NAC of wild-type mice trained to
consume 10% alcohol in a two-bottle free-choice test for alcohol consumption. Alcohol intake was then
ascertained for 1 week after transplantation, and brain sections through the NAC were examined for surviving
grafted cells.
Results: Modified stem cells expressed hDAT and uptaken DA selectively via hDAT. Mice accustomed to drinking
10% ethanol by free choice reduced their alcohol consumption after being transplanted with hDAT-expressing
stem cells. By contrast, control stem cells lacked that effect. Histologic examination revealed surviving stem cells in
the NAC of all engrafted brains.
Conclusions: Our findings represent proof of principle suggesting that genetically engineered stem cells can be
useful for exploring the role of neurotransmitters (or other signaling molecules) in alcohol consumption and
potentially in other aspects of brain function.
Introduction
It has been 50 years since Olds and Milner [1] described
the existence of reward pathways in the brain, based on
their experiments showing that electrical stimulation of
certain brain areas is rewarding to rats. Today’su n d e r -
standing of common reward pathways in the brain
involves the mesocorticolimbic circuitry consisting of
dopaminergic cell bodies in the ventral tegmental area
(VTA) and their projections to terminal areas of the
prefrontal cortex and the “extended amygdala” (the
NAC, substantia innominata, bed nucleus of the stria
terminalis and amygdala). Rewarding stimuli such as
food, sex, and drugs of abuse, including ethanol, result
in the release of DA in terminal areas, particularly the
NAC [2]. Although the dopaminergic mesocorticolimbic
pathway is clearly involved in reward mechanisms,
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remain. We hypothesize that because the DAT regulates
the concentration and duration of synaptic DA available
to stimulate postsynaptic D1 and D2 receptors [3], over-
expression of DAT should decrease the accumulation of
released DA and reduce the ethanol consumption
observed in mice.
To this end, we generated a cell line of C17.2 neural
stem cells that stably overexpresses the hDAT and then
transplanted these cells into the NAC of alcohol-prefer-
ring female C57BL/6J mice. Transplantation of embryo-
nic neurons or neural stem cells into brains of animals
serving as models of neural disorders has recently
attracted more attention. For example, several studies
have shown that transplantation of C17.2 cells into the
CNS can repair a genetic defect such as dysmyelination
[4] and that when overexpressing glucuronidase corrects
lysosomal storage deficiency [5]. Ours is the first report
of using stem cells for modification of neurotransmis-
sion in a model of drug preference. The plasticity and
ease of genetic manipulation of these cells makes them
ideal candidates for neurotransplantation designed to
alter endogenous levels of a single molecule; in this
case, the hDAT. By manipulating the expression of the
hDAT, we sought selectively to affect dopaminergic neu-
rotransmission and ethanol consumption.
Materials and methods
Animals and cell culture
Animal protocols and use were in strict accordance with
the NIH G u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r yA n i -
mals and were approved by the Institutional Animal Care
and Use Committee at the University of Colorado Den-
ver. Male Sprague-Dawley rats (n = 3; 175 to 225 g;
Charles River Laboratories) housed on a 12-h light/dark
cycle with ad libitum food and water were used in
experiments examining synaptosomal DA uptake. We
used female C57BL/6J mice from Jackson Laboratories (6
weeks old at the beginning of the study; 15 to 18 g) for
studies of ethanol preference (n =3 0 )a n dc h r o n o a m -
perometry (n = 5). Mice were housed individually on a
12-h light/dark cycle with food and water ad libitum.
The C17.2 neural stem cells were derived from post-
natal mouse cerebellum, express b-galactosidase [6], and
graft well into rodent CNS. After transplantation, C17.2
cells differentiate into several types of neurons, astro-
cytes, and oligodendrocytes naturally occurring at the
site of transplantation [7], and home into areas of brain
damage [8]. These studies also demonstrate that C17.2
cells do not form tumors, as their growth in contact is
inhibited. The C17.2 neural stem cell line and its clones
were grown in DMEM/10% fetal bovine serum/5% horse
serum, supplemented with glutamine (2 mM), sodium
pyruvate (1 mM), and penicillin/streptomycin/Fungizone
(100× containing 10,000 units penicillin, 10,000 μg
streptomycin, and 25 μga m p h o t e r i c i nB ;G i b c o ,R o c k -
ville, MD), in a 37°C incubator at 5% CO2.
Plasmid construction and transfection of neural stem cells
To ensure a strong expression of hDAT in C17.2 cells
after transplantation and differentiation, a combination
of the cytomegalovirus enhancer and the chicken beta
actin promoter in a pCAIP2 plasmid was used (kindly
provided by Ernest Arenas of Karolinska Institutet). The
construct contains the coding sequence of hDAT, an
intron (IVS), an internal ribosome entry site (IRES), and
t h ec o d i n gs e q u e n c eo ft h ep u romycin resistance gene.
The arrangement facilitates screening of stable transfec-
tants that express hDAT. The hDAT cDNA was obtained
from Jonathan A. Javitch, Columbia University. Exponen-
tially growing C17.2 cells were trypsinized, plated into
10-cm tissue-culture dishes, and grown overnight in
growth medium. Plasmid DNA (20 μg) was mixed with
0.5 ml of CaCl2 (0.25 M) and 0.5 ml BES-buffered saline
(BBS), and incubated for 20 min at room temperature.
DNA/CaCl2/BBS mixture was added drop-wise to the
dishes, which were incubated overnight. C17.mock clones
were transfected with plasmid not containing hDAT
cDNA. The next morning, the cultures were rinsed twice
with Hank’s Balanced Salt Solution (HBSS) and returned
to the growth medium. Forty-eight hours later, the med-
ium was replaced with fresh medium containing puromy-
cin (2.5 μg/ml). The medium containing puromycin was
replaced daily. Six days after selection began, individual
colonies of cells were gently lifted and transferred to indi-
vidual wells of a 96-well plate. Clones were expanded
when they became confluent. C17.hDAT and C17.mock
clones were frozen after DA uptake was determined,
within five to six passages after selection.
Preparation of synaptosomes from dorsal striatum
After decapitation, rat brains were rapidly removed and
placed in an ice-cooled dish where both hemispheres of
dorsal striatum were dissected. Striatal tissue was homoge-
nized in 2 ml of ice-cold phosphate buffer (3.3 mM
NaH2PO4 + 12.7 mM Na2HPO4) containing 0.32 M
sucrose (pH 7.4) with a glass homogenization tube and a
Teflon pestle. Homogenization was followed by centrifuga-
tion at 1,000 g for 12 minutes at 4°C. The supernatant was
centrifuged at 12,500 g to isolate the P2 pellet and then
resuspended at 15 mg/ml (wet weight of tissue). The
resuspended P2 synaptosomal pellet was further washed
by centrifugation to isolate the P4 synaptosomal pellet,
which, on resuspension, was used in the uptake assay.
[
3H]DA uptake in synaptosomes
Chemicals were purchased from RBI/Sigma (St. Louis,
MO, USA) with the following exceptions: (-)-cocaine
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Abuse (Research Triangle Institute International,
Research Triangle Park, NC), and [
3H]DA was pur-
chased from PerkinElmer Life Sciences (Boston, MA,
USA). Striatal synaptosomal tissue was incubated with
assay buffer (134 mM NaCl, 240 mM KCl, 65 mM
CaCl2,7 0m M MgSO4,3 . 3m M NaH2PO4,1 2 . 7m M
Na2HPO4,1 1m M glucose, and 1 mM ascorbic acid, pH
7.4) containing 1 μM pargyline for 10 minutes at 37°C.
[
3H]DA was added at a final concentration of 0.5 nM
(54.1 to 59.3 Ci/mmol) in addition to increasing concen-
trations of unlabeled DA (0.5, 5, 50, 500, 1,000, and
10,000 nM). The uptake assay was performed at 37°C
for 3 minutes. Nonspecific uptake of [
3H]DA was deter-
mined in samples incubated with 1 mM cocaine. The
assay was halted by placing the samples on ice and add-
ing 3 ml of ice-cold 0.32 M sucrose solution before fil-
tering through Whatman GF/C glass microfiber filters
with a cell harvester. The filters were washed an addi-
tional 2 times with the sucrose solution before being
placed in scintillation vials filled with 4 ml of scintilla-
tion cocktail. Radioactivity was determined with liquid
scintillation spectrometry. The protein concentration of
the P4 synaptosomal pellet was determined according to
the method of Bradford (1976), by using bovine serum
albumin as the standard. Km and Vmax values for [
3H]
DA uptake were calculated with nonlinear regression fit-
ting by using Graph Pad Prism software (San Diego,
CA). All uptake studies involved three independent
experiments with samples tested in triplicates.
[
3H]DA uptake in cultured neural stem cells
After thawing, clones were split once by trypsinization
and plated into 12-well tissue-culture plates that were
precoated with poly-L-lysine (Sigma; 10 μg/ml). Cells
were grown for 48 hours before uptake was measured.
The cells were rinsed and then assayed at 37°C in
Krebs-Ringer HEPES buffer (KRH; 120 mM NaCl, 4.7
mM KCl, 2.2 mM CaCl2,1 . 2m M Mg SO4,1 . 2m M
KH2PO4,1 0m M glucose, 10 mM HEPES, pH 7.4) sup-
plemented with 10 μM pargyline, 10 μM ascorbic acid,
and 10 μM catechol. Assays (1 ml) included 50 nM [
3H]
DA (54.7 to 59.3 Ci/mmol). Nonspecific [
3H]DA accu-
mulation was determined in the presence of 1 mM (-)
cocaine hydrochloride. After 10 minutes of incubation
at 37°C, uptake was terminated by quickly washing the
cells 3 times with 1 ml of ice-cold KRH. Cells were then
solubilized in 0.5 ml of 3% trichloroacetic acid for 60
minutes with gentle shaking. Accumulated [
3H]DA was
determined by liquid scintillation counting. Clones
s h o w i n gr o b u s tu p t a k ea t5 0n M [
3H]DA were then
chosen for further studies of saturation kinetics in the
presence of various concentrations of DA, or selectivity
in the presence of 1 μM GBR 12909, desipramine, or
fluoxetine. Kinetic parameters were calculated as
described earlier.
Stem cell transplantation
C17.hDAT or C17.mock transfected cells were thawed
into a 60-mm tissue-culture plate 4 to 7 days before
transplantation. They were rinsed 4 to 6 hours after
thawing and then split by trypsinization after 3 or 4
days, when they were 85% confluent. On the day of sur-
gery, cells were used only if less than 90% confluent.
They were trypsinized, spun at 300 g, and rinsed 4 times
with HBSS before resuspension in HBSS at a density of
50,000 cells/μl. The cells were kept above ice until
transplanted. Cells left over after surgery were plated
into DMEM growth media and allowed to attach before
staining with x-gal to verify b-galactosidase expression.
Mice were anesthetized with isoflurane, and holes were
drilled in the skull bilaterally at 1.4 mm anterior, and
±0.8 mm lateral to bregma (coordinates from [9]). A
stainless steel guide cannula (27 gauge) with solid blunt
insert was lowered 3 mm below the dura. The solid
insert was then replaced with a 29-gauge cannula, which
extended 1.5 mm past the end of the guide cannula and
was attached to PE tubing and a 10-μl Hamilton syringe.
Then 100,000 cells were injected from the cannula at a
rate of 1 μl/min, while the cannula was raised 1 mm,
depositing the cells over a 1-mm track. The cannula was
left in place for an additional 2 minutes before removing
it from the brain. Three groups of mice (nine per group)
received either bilateral saline injection into the NAC, or
bilateral transplants of C17.hDAT cells, a clone with
functional DA transporter, or C17.mock, a clone mock-
transfected with an empty plasmid.
Two-bottle choice test
Alcohol preference was tested in 30 mice by introducing
two water bottles for 3 days, and then replacing the
water in one of the bottles with ethanol (3% wt/vol for 6
days, then 10% wt/vol for 8 days). Body weight and the
volume of water and ethanol consumed from each bottle
were measured every 3 days, at which time fresh ethanol
and water were provided, and the positions of the bot-
tles switched. The mice were given 3 days without etha-
nol before transplantation, followed by 3 days of
recovery before preference was again tested with 10%
ethanol in one of the two bottles. The ratio of the
volume of ethanol to the total fluid consumed was cal-
culated. Ethanol consumption was calculated in grams
e t h a n o l / k gb o d yw e i g h t / d a y .T h r e em i c ew e r ee l i m i -
nated based on their pretransplantation ratios (<0.55),
leaving nine mice per group for transplantation (27
mice total). Posttransplant alcohol consumption was not
measured for one animal in the C17.mock group
because it died postsurgically. All animals that survived
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these animals were included in the alcohol-consumption
analysis.
Electrochemical recording of DA clearance
The method used is explained in detail in Hoffman
et al. [10] and modified by Gulley et al. [11]. DA clear-
ance was determined in C17.mock clone and C17.hDAT
clone 5 to 7 days after transplantation into the right and
left, respectively, cerebral cortex of each of the five mice
used. Mice were killed by cervical dislocation, and their
brains were rapidly chilled in ice-cold artificial cere-
brospinal fluid (aCSF; 126 mM NaCl, 2.9 mM KCl, 1.5
mM MgCl2,2 . 5m M CaCl2,1 . 4m M NaH2PO4,1 0m M
glucose, 25 mM NaHCO3 and 200 μM ascorbate, con-
tinuously bubbled with 95% O2/5% CO2; pH 7.4). Coro-
nal brain sections (400 μm) containing the transplanted
cell tracks in the cerebral cortex were cut with a Vibra-
tome (Ted Pella, Inc., Redding, CA). After slice recovery
at 22°C in aCSF for ≥1 hour, slices were transferred to a
recording chamber, perfused with aCSF at a rate of 2
ml/min, and maintained at 32° to 33°C. High-speed
chronoamperometric measurements were carried out by
using an IVEC-10 system (Medical Systems, Greenvale,
NY). Single-carbon-fiber electrodes (30 μmd i a m e t e r ,
coated with 5% wt/vol Nafion solution; Sigma-Aldrich,
St. Louis, MO) were calibrated in vitro and used only if
their responses were linear to DA (r
2 ≥ 0.997) and selec-
tive (≥1,000:1) for DA over ascorbic acid. Electrode-
micropipette assemblies were constructed by attaching a
micropipette (A-M Systems, Everett, WA; 10- to 15-μm
tip diameter) to the electrode at a distance of 200 to
250 μm. This assembly was lowered to a depth of 100
to 150 μm from the slice surface into the cerebral cortex
just adjacent to the surgical track left from the cell
implantation. To detect DA, square-wave pulses of 0.00
to +0.55 V, with respect to an Ag/AgCl reference elec-
trode, were applied at a frequency of 5 Hz. DA (200 μM
in phosphate-buffered saline (pH 7.4, adjusted with
NaOH) and 100 μM ascorbic acid) was pressure-ejected
(6 to 15 psi for 0.1 to 2 seconds; Picospritzer II; General
Valve Corp., Fairfield, NJ) until a maximal DA signal
amplitude (Amax)o f1t o3μM was obtained. DA was
pressure-ejected with these settings kept constant at 5-
minute intervals for a minimum of three consistent
recordings (≤15% variation in Amax values) at a particu-
lar recording site. Clearance time (T80;s e c o n d s ) ,t h e
time for the signal to increase to Amax and then to
decay by 80%, and clearance rate (μM/sec), the change
in DA signal amplitude between the T20-60 time points
and the most linear portion of the DA signal-decay
curve, were measured. For each transplant, two to four
recording sites in different brain slices were sampled,
and these were used to calculate mean values for each
parameter for the two types of stem cells. Mean values
± SEM are reported for n = number of mice.
Immunohistochemical analysis
Animals were deeply anesthetized and transcardially
perfused with saline followed by 4% paraformaldehyde.
The brains were cryoprotected in 30% sucrose for 2
days before sectioning at 40 μm. Sections were rinsed
and quenched in 1% H2O2 for 10 minutes before block-
ing in 10% normal goat serum in Tris-buffered saline
containing 1% BSA and 0.1% Triton X-100 (TBST). Sec-
tions were incubated in a primary antibody to hDAT
(1:200, Chemicon) overnight at room temperature. After
rinsing, sections were incubated in anti-rat IgG (1:250,
Vector) for 1 hour at room temperature. After addi-
tional rinses, incubation with ABC solution (Vectastain,
Vector) for 1 hour and then nickel-enhanced diamino-
benzidine (Vector) permitted visualization of labeled
cells.
Beta-galactosidase activity assay and localization of
transplanted cells
Cells in culture or sections were stained for b-galactosi-
dase by incubating with 5-bromo-4-chloro-3-indolyl-b-
D-galactosidase (X-gal) (1 mg/ml in 5 mM potassium
ferrocyanide/potassium ferricyanide and 2 mM MgCl2
buffer) for 2 to 18 hours at 37°C. Because the actual
number of transplanted cells would be impossible to
count, the localization of transplanted cells in each
group was summarized by scoring the relative abun-
dance of b-galactosidase-positive cells present in a grid
location overlaid on three stained sections from each
mouse. Sections showing the most cells bilaterally were
chosen for analysis, roughly approximating rostral, mid-
dle, and caudal extent of the track. Some transplants
were localized bilaterally in more anterior sections of
the NAC, and some were slightly more caudal in the
NAC. Each square of the grid was scored as containing
no cells (0), a few sparse cells in less than one fourth of
the square (1), sparse cells covering about half of the
square (2), densely packed cells occupying about half of
the square (3), densely packed cells occupying three
fourths of the square (4), or densely packed cells entirely
filling the square (5). The scores of each animal in a
group of either anterior or posterior NAC were summed
and used as the z coordinate for a colorized xyz isocon-
tour plot (SigmaPlot; SysStat, Point Richmond, CA),
where x and y represented the square coordinates of the
g r i d( 0 ,w h i t e ;1 ,p u r p l e / b l u e ;2 ,d a r kg r e e n ;3 ,l i g h t
green; 4, yellow; 5, orange/red). For clarity, details of
this method are illustrated in example micrographs in
Supplementary figure S1 in Additional file 1. The num-
ber of sections contributing to each cumulative plot was
between 9 and 15.
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Data are reported as the mean ± SEM. One mouse from
each group was eliminated because their alcohol prefer-
ence ratio was <0.55 before transplantation. The inhibi-
tion of DA uptake by selective inhibitors was analyzed
by one-way ANOVA by using SigmaStat with Tukey
post hoc comparisons. Body weight and total daily fluid
consumption were averaged to yield pre- and postsur-
gery values. Alcohol consumption (grams ethanol/kg
body weight/day) was averaged at each concentration of
ethanol before transplant and after transplant. Ethanol
consumption, total fluid consumption, and body-weight
data were analyzed by two-way ANOVA by using ver-
sion 6.5 of GB-STAT (Dynamic Microsystems Inc., Sil-
ver Spring, MD) with DAY as a repeated measure. Post
hoc analyses were done with the Fisher LSD test.
Results
Generation and characterization of hDAT-expressing
neural stem cells
Because reliable and enduring expression of functional
hDAT is required for transplantation, we first generated
clones of C17.2 neural stem cells that stably expressed
hDAT under the control of a chicken b-actin promoter
and a cytomegalovirus enhancer. This promoter has
been used successfully to express a transcription factor,
Nurr1, and glial cell line-derived neurotrophic factor in
C17.2 stem cells [12,13]. Two plasmids were created,
one with the hDAT cDNA (Figure 1a) and the other
(mock plasmid) lacking any cDNA at the position of
hDAT cDNA. Cells were transfected with these plas-
mids, by using the calcium phosphate method, and were
s u b s e q u e n t l yg r o w ni nt h ep r e s e n c eo fp u r o m y c i nf o r
selection.
After selection with puromycin, 36 hDAT-transfected
colonies and 36 mock plasmid colonies were grown
individually in 96-well plates. Sixteen of the hDAT
clones and eight of the mock plasmid clones were ran-
domly chosen, and specific [
3H]DA uptake was deter-
mined (50 nM [
3H]DA ± 1 mM cocaine). Seven of 16
hDAT clones assayed exhibited moderate to high levels
of uptake (Figure 1b). Specific [
3H]DA uptake was unde-
tectable in all mock plasmid transfected clones, as well
as in nine of the hDAT clones. Four of the hDAT
clones (a7, b1, b7, and c1) that exhibited a wide range
of uptake levels were chosen for full kinetic uptake ana-
lyses. Results are shown for the b7 clone (Figure 1c),
which was selected for transplantation experiments (see
later), and from this point on, referred to as C17.hDAT.
The clones exhibited affinities (Km) between 5 and 9
μM and a range of saturation velocities (Vmax) between
43 and 180 pmol/min/mg protein. To achieve efficient
uptake kinetics from genetically modified clones, their
uptake should resemble that of the naturally occurring
DAT. The Vmax values from our DAT clones examined
were found to be comparable to those obtained from rat
striatal synaptosomes, with somewhat lower affinities
(Km of 0.10 ± 0.02 μM and Vmax of 108 ± 27 pmol/min/
mg protein; Figure 1d) and those recently reported for
rat NAC synaptosomes (Km of 0.20 ± 0.04 μM and Vmax
of 57 ± 11 pmol/min/mg protein) [14]. The four clones
also exhibited selectivity for [
3H]DA transport, as GBR
12909 (DAT inhibitor) blocked specific [
3H]DA uptake
by 90% (Figure 1e). By contrast, desipramine (norepi-
nephrine transporter inhibitor) and fluoxetine (serotonin
transporter inhibitor) had no effect on the uptake.
In addition to the efficient and selective uptake of DA
resembling naturally occurring DAT, other reasons for
choosing the C17.hDAT clone for transplantation
included (1) a consistent b-galactosidase expression in
more than 95% of this clone’s cells, an asset for identifi-
cation of the cells in transplants; (2) a good proliferative
capacity crucial for expansion before transplantation;
and (3) a high survival rate after transplantation into the
CNS. Although the presence of functional DAT is an
unquestionable indication of the transporter’sa p p r o p r i -
ate insertion into the cell membrane, we additionally
quantitated the expression levels of hDAT by using
Western immunoblotting (Figure 1f). This analysis
revealed that the C17.hDAT clone expressed two forms
of hDAT. The first was a 68-kDa mature form, which is
glycosylated and exclusively found inserted into the cell
membrane [15]. The second form of hDAT was a band
at 50 kDa, consistent with an immature, unglycosylated
form usually found in the cytoplasmic compartment.
The C17.hDAT clone expressed about 95% of the
hDAT as the mature (68 kDa) form and about 5% as
the immature (50 kDa) form. The naïve C17.2 stem cells
and the mock-transfected f2 clone (C17.mock) con-
tained only trace amounts of immunoreactivity for
hDAT.
Establishing alcohol-drinking model in wild-type mice and
transplantation of hDAT-expressing neural stem cells into
the NAC
Before transplantation into the NAC, the mice were
allowed to develop a preference for alcohol drinking, the
variable that we would then attempt to alter by grafting
hDAT-expressing stem cells. A timeline for the in vivo
experiments is shown in Figure 2. Singly housed mice
were given free and unrestricted choice of water or
ethanol from two bottles for 24 hours a day in their
home cage (two-bottle preference test). The initial etha-
nol concentration was 3% for 6 days and then increased
to 10% for the next 8 days. By the end of this training
period and before transplantation, mice consumed on
average 16 g/kg/day of alcohol, and about 75% of their
total fluid intake was from the alcohol-containing bottle.
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increased similarly in all mice before transplantation.
Initially the preference ratio (proportion of ethanol rela-
tive to total fluid consumed) was around 0.50, but gra-
dually increased until day 14, when most mice had
ratios above 0.70 (mean, 0.75 ± 0.04; n =3 0 ) .A l la n i -
mals with preference ratios above 0.55 (n =2 7 )w e r e
included and divided equally based on their preference
ratio among the three groups receiving transplants. For
3 days before, as well as 3 days after, transplantation, all
Figure 1 Human DAT construct used in the stable transfection of C17.2 neural stem cells and characterization of its functional
expression in selected clones. (a) Expression vector used for transfection. The construct contained the cytomegalovirus (CMV) enhancer
element, chicken b-actin promoter, the coding sequence of hDAT, an intron (IVS), an internal ribosome entry site (IRES), and the coding sequence
of the puromycin resistance gene. (b) Clones that survived selection with puromycin were screened for specific [
3H]DA uptake (±1 mM cocaine).
Several clones were chosen for expansion and further analysis based on their uptake of DA (arrows). Clones b7 (C17.hDAT) and f2 (C17.mock),
identified by black arrows, were chosen for the transplantation and alcohol-consumption experiments. (c) Kinetic analysis of specific [
3H]DA uptake
in a C17.hDAT clone. Three independent experiments revealed average values for Km of 5 ± 1 μM and Vmax of 180 ± 5 pmol/min/mg protein. (d) In
similar [
3H]DA-uptake kinetic experiments, rat striatal synaptosomes had values for Km of 0.10 ± 0.02 μM and Vmax of 108 ± 27 pmol/min/mg
protein (n = 3). (e) Selectivity experiments in the C17.hDAT clone revealed that [
3H]DA uptake was blocked only by the DAT inhibitor (GBR 12909, 1
μM), but not by selective inhibitors of norepinephrine or serotonin transporters, desipramine, or fluoxetine (1 μM), respectively. *P < 0.01 compared
with control, Tukey test (three independent experiments). (f) Western immunoblot for hDAT showing both mature, glycosylated (DAT) and
immature, nonglycosylated forms of hDAT (ngDAT) in the C17.hDAT clone. Beta-actin was detected as a control for protein loading.
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potential adverse effects of ethanol during surgery and
recovery.
On day 18, two groups of animals were transplanted
bilaterally with 1 × 10
5 viable cells (either C17.hDAT
c l o n eo rC 1 7 . m o c kc l o n e )i nt h eN A Co ne a c hs i d eo f
the brain. Saline injected bilaterally into the NAC served
as a surgical control (the third group that we refer to as
saline control). Each transplant was delivered in a
volume of 2 μl, by using a stainless steel transplant can-
nula (see Materials and methods). To assure that trans-
plantation did not alter normal patterns of body weight
and total fluid consumption, both parameters were mea-
sured every 3 days throughout the study. Body weight
increased in all groups over t h ec o u r s eo ft h ee x p e r i -
ment (F1, 23 = 72.35; P < 0.0001; Table 1). However, it
did not differ among the transplant groups (F3, 23 =
0.77; P = 0.47), and no significant interaction was found
(F2, 23 = 1.24; P = 0.31). The values are similar to body
weights reported for female C57BL/6J mice between
6 weeks and 10 weeks of age (Jackson Laboratories).
Similarly, total fluid consumption increased over
t h ec o u r s eo ft h ee x p e r i m e n t( F1, 24 = 9.27; P = 0.006;
Table 1). However, it did not differ among groups (F3, 24 =
0.19; P = 0.83), and no significant interaction was observed
(F2, 24 = 1.16; P = 0.33). The lack of differences in body
weight and fluid consumption between the groups indi-
cates that the transplantation surgery was not detrimental
to the general health of the animals. Additionally, no
noticeable changes were observed in the behavior of the
mice after surgery.
Characterization of hDAT-expressing neural stem cell
grafts
Graft placement, determined from X-gal staining (Figure
4a and 4b) 10 days after transplantation, revealed that
the majority of transplanted cells remained either within
the transplant track or in its immediate vicinity, with a
few cells seen 100 to 200 μm away from the track. X-gal
staining was evident in all of the mice transplanted with
C17.hDAT or C17.mock stem cells. The localization of
the transplanted cells in all of the mice in each of these
two groups was summarized by scoring the abundance
of transplanted cells in three representative coronal sec-
tions from each mouse (Figure 4c). The transplants
were targeted into the NAC, which is a relatively small
Figure 2 Experimental timeline. Animals were allowed free choice between water or ethanol (3% for days 1 to 6, 10% for days 7 to 14).
Transplants (saline control, C17.mock, or C17.hDAT; n = 9 in each group) into NAC, were performed after 3 days off alcohol, and then preference
for 10% ethanol was measured again after 3 days of recovery from surgery for an additional 6 days. All animals were sacrificed 10 days after
transplantation.
Figure 3 Determination of alcohol consumption before
transplantation. Ethanol consumption (g/kg/day) was measured
during the acquisition of the alcohol-preference phase over 14 days
before transplant (day 17) in each group of animals. Consumption
increased with time and ethanol concentration.
Table 1 Body weight and daily fluid consumption before
and after transplantation (TX)
Body weight (g) Average daily fluid consumption
(ml/day)
Before TX After TX Before TX After TX
Saline 18.8 ± 0.36 19.8 ± 0.36 5.4 ± 0.21 5.7 ± 0.26
C17.mock 18.2 ± 0.29 19.3 ± 0.54 5.0 ± 0.14 5.7 ± 0.24
C17.hDAT 18.5 ± 0.26 20.0 ± 0.36 5.2 ± 0.21 5.6 ± 0.33
C17.hDAT, C17.2 neural stem cell line stably expressing a construct containing
the hDAT sequence; C17.mock, C17.2 neural stem cell line stably expressing a
construct lacking the hDAT sequence; TX, transplantation.
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Page 7 of 13Figure 4 Histologic analysis of grafted neural stem cells. (a) A representative coronal section from a mouse transplanted with C17.hDAT
clone. Section stained for b-galactosidase by using x-gal histochemistry revealed bilateral distribution of surviving grafted cells 10 days after
transplantation. (b) Magnified area of the graft shows cells with various morphologies; some extending processes. (c) Summary of the
localization of transplanted cells. Relative abundance of x-gal-positive cells in all mice in both groups receiving cell transplants is representeda s
a colorized xyz isocontour plot (for details, refer to Materials and methods). Cumulative scores from three sections per mouse ranged from few
cells (1, blue) to many densely packed cells (5, red). For clarity, details of this method are illustrated in example micrographs in Supplementary
Figure S2 in Additional file 3. (d) Coronal section at the level of NAC stained with an antibody against DAT. Although the antibodies used do
not distinguish endogenous DAT from that found in the transplanted C17.hDAT cells, the ectopic expression of DAT evident in the cortical
region of the transplant track is consistent with the exogenous hDAT. Such ectopic placement of a transplant is not representative of other
animals examined in this study. (e) In contrast, a transplant of the C17.mock stem cells into striatum, shown here in a coronal section, is not
labeled with the anti-DAT antibody and is clearly visible as a vertical clear track in the right hemisphere, which labeled strongly, revealing the
endogenous DAT. CC, corpus callosum; AC, anterior commissure. Scale bars = 1 mm for panels a and c through e; and 200 μm for panel b.
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Page 8 of 13structure in the mouse brain, reaching a maximal width
of 2 mm [9]. Although current technology makes it dif-
ficult to achieve consistently more precise graft place-
ment, continual refinements in the transplantation
technique and equipment will enable more precise tar-
geting in the future.
Currently available anti-DAT antibodies used recog-
nize both endogenous (murine) and exogenous (human)
DAT. Nonetheless, we were able to observe (albeit
rarely) ectopic localization and elevated levels of DAT
immunoreactivity in sections obtained from animals
receiving the C17.hDAT clone (Figure 4d), whereas in
contrast, transplants of the C17.mock neural stem cells
completely lacked DAT-immunoreactivity (Figure 4e).
To confirm that C17.hDAT cells retain their ability to
take up DA after transplantation, we measured the rate
of DA clearance in transplanted cells in a group of five
mice. Clearance of locally applied exogenous DA, as
measured by high-speed chronoamperometric recording,
is determined to a large extent by the activity of the
DAT [11,16]. Cortex was used as the site for transplan-
tation because its relatively sparse DA innervation and
low DA clearance rate, relative to striatum, provides a
low back-ground clearance and would thereby enhance
detection of any increase in clearance rate due to the
hDAT-expressing stem cells. Consistent with this idea,
the DA clearance rate in brain slices from naïve rats is
threefold higher in striatum (0.115 ± 0.035 μM/sec; n =
4) than cerebral cortex (0.036 ± 0.009; unpublished
observations, Gaynor A. Larson and Nancy R. Zahniser).
Similarly, we observed a fourfold higher striatal clear-
ance rate in brain slices from naïve mice (striatum,
0.148 μM/sec; cortex, 0.032; n = 2).
Here, we used this method to compare DA clearance
in C17.hDAT and C17.mock grafts transplanted 5 to 7
days earlier into mouse cerebral cortex. Brain slices
were prepared from five mice, each of which had the
C17.mock control cells implanted into the right cerebral
cortex, and the C17.hDAT cells, into the left cortex. A
trend for a faster clearance rate (20% increase) was
noted in the C17.hDAT transplants (0.054 ± 0.009 μM/
sec), compared with C17.mock (0.045 ± 0.006; Table S1
in Additional file 2 and Supplementary figure S2 in
Additional file 3). Both clearance rates were somewhat
faster than the rate we observed previously in naïve
mouse cortical slices (see earlier).
Transplantation of DA-sequestering neural stem cells
reduces intake of alcohol in wild-type mice
Measurement of alcohol consumption was resumed 3
days after the surgery for an additional 6 days. In the
majority of the animals that received saline or C17.mock
cells, the preference for 10% ethanol remained
unchanged or slightly increased after transplantation
(Figure 5). Analysis of the average alcohol consumption
before transplantation (3% and 10%) and postsurgically
showed a significant main effect of Day (F2, 46 =1 9 0 . 8 5 ;
P < 0.0001), but not Group (F2, 23 =0 . 9 9 ;P =0 . 3 9 ) .
Additional analysis revealed a significant interaction of
Day and Transplant group (F4, 46 =2 . 8 6 ;P =0 . 0 3 4 ) .
After transplantation, the mice in the C17.hDAT group
significantly reduced their ethanol consumption by 18%
from 17 to 14 g/kg/day when compared with the C17.
Figure 5 Comparison of alcohol consumption before and after
transplantation. (a) Consumption of 10% ethanol was lower after
transplantation in mice transplanted with C17.hDAT cells when
compared with mice receiving C17.mock cells. While average pre-
versus posttransplant consumption was reduced in most of the C17.
hDAT animals, it remained unchanged or slightly elevated in saline
control and C17.mock groups, respectively. *P < 0.05 comparing
posttransplant C17.hDAT with posttransplant C17.mock group. (b)
Average consumption of 10% alcohol before and after
transplantation in individual animals. The effects on consumption
between pre and post measurements are depicted by different line
colors: red (reduction in consumption), black lines (increase), and
blue (no change). Mean group value is represented by a green
horizontal bar for each group. Although five of nine C17.hDAT
animals reduced their consumption, only two of eight C17.mock
animals did. Pre, before transplantation; post, after transplantation.
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Page 9 of 13mock group (P < 0.05; Figure 5a). Values for individual
animals in each group are shown in Figure 5b.
Discussion
Here, we demonstrate that overexpression of DAT alters
ethanol drinking in C57BL/6 mice. Because mesocorti-
colimbic DA is postulated to contribute to alcohol con-
sumption, we transplanted neural stem cells modified to
overexpress the hDAT into the NAC of C57BL/6 adult
female mice. We postulated that grafted C17.hDAT cells
that express high levels of the DAT should clear the
extracellular DA faster than the surrounding tissue.
High-speed chronoamperometric measurements showed
a trend toward faster DA clearance rates in cortical C17.
hDAT transplants compared with C17.mock transplants.
The reduction in alcohol intake that was observed in
mice with the C17.hDAT transplants in NAC is consis-
tent with the idea that NAC DA might affect ethanol
consumption.
Our ethanol-consumption data are in agreement with
studies showing that D1 and D2 receptor antagonists,
injected systemically or locally into the NAC, decrease
alcohol consumption and operant responding to alcohol
[17,18]. Mice lacking D1 receptors also show decreased
ethanol consumption in a two-bottle choice test com-
pared with wild-type mice [19]. Extracellular DA levels
are increased in the NAC by systemic alcohol adminis-
tration [20-23]. These findings are consistent with the
theory that DA neurotransmission in the NAC is neces-
sary for the rewarding properties of alcohol. However,
despite numerous studies examining the involvement of
the dopaminergic system in reward, the precise role for
DA in drug addiction is still far from clear.
The DAT is the primary physiologic mechanism for
terminating DA neurotransmission in the CNS. By inhi-
biting the DAT, drugs of abuse like cocaine and phency-
clidine preferentially increase extracellular DA in NAC,
as compared with dorsal striatum. Ethanol also elevates
DA levels in the NAC. However, unlike cocaine, ethanol
does this by increasing the firing of DA neurons in the
VTA [24]. Alcohol-preferring rats will self-administer
ethanol into the VTA [25]. Ethanol exerts its actions by
potentiating GABAergic inhibition of inhibitory inter-
neurons in the VTA [26,27], leading to disinhibition of
DA neurons. As with other drugs of abuse, the
increased firing of VTA neurons results in enhanced
release of DA in the NAC [22,28,29].
Some studies have reported that D1 and D2 receptor
agonists, as well as pharmacologic agents that elevate
DA levels, also reduce ethanol self-administration
[30-32]. Conceivably, the reduced drug-seeking behavior
resulting from activation of D1 or D2 receptors in these
studies may be due to either a decrease in the rewarding
properties of alcohol or a feedback-mediated elevation
of endogenous DA, which reduces the drive for alcohol
[19]. Enhancing extracellular DA in the NAC with
GBR12909, a DA-uptake inhibitor, decreased DA levels
in the VTA, suggesting the presence of a negative-feed-
back loop in the regulation of DA release [33]. The reg-
ulation of DAT by alcohol might also have a role in the
control of alcohol intake, as supported by the observa-
tion that chronic (8-week) consumption of 15% alcohol
increases DA uptake in the NAC of selectively bred
high-alcohol-drinking (HAD) female rats [34]. Although
our study differs by using wild-type female mice in a
shorter (27-day) experimental paradigm with a maxi-
mum alcohol concentration of 10%, both studies imply
that plasticity in the reward circuitry involving DAT
might be a modifier of alcohol drinking.
Recently, two alternative approaches for overexpres-
sion of DAT have been used. The first is a global one
achieved by creating transgenic mice harboring a bacter-
ial artificial chromosome containing the murine DAT
gene [35]. Although these mice display an increased
locomotor response to amphetamine compared to wild-
type mice, they have a reduced operant response to a
natural sweet-food reward, a finding that in principle
supports our observations. A second study used direct
injection into rat NAC of a lentiviral construct encoding
rat DAT, which led to an impulsive and risk-prone phe-
notype [36]. This approach varies from ours in that len-
tivirus-infected neurons in the NAC can retrogradely
transport DAT product into the VTA, whereas the
hDAT expressed by C17.hDAT cells in our study is not
transported and remains within the confines of the
engrafted area.
Alcohol-preferring strains of rats, as well as the
C57BL/6J mouse used here, have lower basal levels of
dopaminergic function (decreased DA levels and turn-
over) than do non-alcohol-preferring strains [30,37,38].
In the C57BL/6J mice, enhancing synaptic DA decreased
ethanol consumption, an effect that could be mimicked
with DA-receptor agonists or blocked by DA-receptor
antagonists [30]. These results suggest that voluntary
ethanol consumption is higher in these mice because of
increased drive (that is, they need more ethanol to get
the same reward). If this were simply the case, we might
have expected that the overexpression of DAT (lowering
the amount of released DA to interact with postsynaptic
receptors) would increase drive and ethanol consump-
tion. Our finding of decreased ethanol consumption
after the overexpression of DAT is inconsistent with the
theory that increased preference and consumption in
C57BL/6 mice is due to increased drive. The alternative
theory, as to why the hypodopaminergic C57BL/6
mouse is alcohol preferring, is that the ethanol-induced
release of DA on top of a low baseline is perceived as a
larger reward (signal-to-noise difference). However, by
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actions of DA and thereby reducing the stimulation of
postsynaptic DA receptors, leading to decreased con-
sumption. Thus, our mice are not simply hypodopami-
nergic, but might rather have dopaminergic
neurotransmission through the NAC-reward pathway
selectively inhibited.
Because we have measured DA clearance by stem cell
transplants within cerebral cortical slices, in future
experiments, both behavior and DA clearance must be
measured simultaneously in the mice to assess whether a
relation exists between changes in ethanol drinking and
DA uptake by the C17.hDAT stem cells transplanted into
the NAC. It is intriguing to speculate that stem cells
engineered to express hDAT will adjust their capacity to
clear DA, based on the transplant location in the brain or
the level and duration of exposure to ethanol or both.
Although the current study was not specifically designed
to answer this question, addressing this issue represents
an important direction for future explorations.
We chose to examine female C57BL/6J mice in our
study based on the reported higher preference seen in
females than males of this strain of mice. Because we
did not use high and aversive concentrations of ethanol
for our posttransplantation preference, an increase in
consumption or preference ratio would have been
detectable in our study. Lesions of the NAC with 6-
hydroxydopamine decrease the acquisition, but not the
maintenance of alcohol preference in alcohol-preferring
rats [39]. This study suggests that preference, once
established, is difficult to disrupt. It is possible that the
observed effect on alcohol consumption would have
been greater in magnitude if we had performed the
transplants before the acquisition of alcohol preference.
Alternatively, stem cells engineered to support higher
dopamine clearance in vivo might also produce a larger
reduction in ethanol consumption. The extent to which
the posttransplantation decreases in alcohol intake
might reflect changes in the reinforcing properties of
ethanol should be confirmed in the future by using
operant self-administration.
Studies presented here examine a very short experi-
mental period. Future experiments will be designed to
examine long-term survival of the transplanted stem
cells, expression of hDAT, DA clearance, and to answer
whether the effects on alcohol consumption persist.
Long-term outcomes assessed over several weeks (or
longer) will be therefore necessary to test our approach
fully and to determine its broader usefulness.
Blood ethanol concentration (BEC) depends on alcohol
intake and on the pharmacokinetics of alcohol metabolism,
both of which vary between species and genders. Time of
sampling is also critical for the estimation of BEC. In noc-
turnal animals such as mice, more than 90% of daily
alcohol intake occurs during the dark [40]. When access to
alcohol is continuous, C57BL/6J females drink as much as
twice the amount of 10% alcohol typically consumed by
the males [41]. In one report, male C57BL/6J mice drinking
10% ethanol in the unrestricted-access two-bottle prefer-
ence test (same paradigm as the one used by us) exhibited
BECs up to 150 mg/dl (in the dark) while consuming
about 5 g/kg/day [40]. In a similar experiment, which used
a drinking-in-the dark paradigm with a 4-hour 20% alcohol
access, a mixed group of male and female C57BL/6J mice
consumed on average 7 g/kg of alcohol in 4 hours, which
resulted in a BEC of 100 mg/dl [42]. Because female mice
used in our study had alcohol intakes between 15 and 18
g/kg/day, it is likely that the resulting BECs could have
been even higher, particularly if measured in the dark.
Because in humans, BECs around 80 mg/dl (the legal limit
for driving while impaired in the United States) coincide
with altered emotions, loss of control of fine motor move-
ments, and affected driving performance [43], our con-
sumption model is relevant to the human condition.
Our study demonstrates a novel strategy of using stem
cell transplantation for moderating alcohol effects and
intake, and our approach may provide future insights
into better understanding of the mechanism of alcohol
reward and addiction. This technique, when combined
with the use of stem cells capable of metabolizing mole-
cules of interest, could be of importance in studies
requiring sequestration and degradation of molecular
signals as well as neurotoxins. For example, glutamate
neurotoxicity can be reduced by increasing expression
of glutamate transporters [44]. Similar approaches could
be used to study multidrug resistance-associated trans-
porter proteins, which are important in the context of
treatment of epilepsy and brain cancers [45] and trans-
port across the blood-brain barrier for delivery of neuro-
pharmaceuticals into the CNS [46].
Conclusions
In summary, we determined that ethanol consumption
is reduced by grafting stem cells overexpressing hDAT
in the NAC. These data support the hypothesis that
released DA in the NAC contributes to alcohol prefer-
ence, and proposes DAT as a target for reducing alcohol
drinking. Our findings also provide the first evidence for
use of stem cells as vehicles for modification of neuro-
transmitter-mediated actions in the CNS.
Additional material
Additional file 1: Figure S1. Micrographs illustrating the method
used for estimation of relative abundance of x-gal-positive cells in
transplants. The localizations of transplanted cells in the C17.hDAT
group (a) and C17.mock. (b) were summarized by scoring the relative
abundance of x-gal-positive cells present in a grid location overlaid on
three stained sections from each mouse. Each square of the grid was
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Page 11 of 13scored and assigned a color in the isoplots in the following way: 0,
containing no cells (white); 1, a few sparse cells in less than one fourth
of the square (purple/blue); 2, sparse cells covering about half of the
square (dark green); 3, densely packed cells occupying about half of the
square (light green); 4, densely packed cells occupying three fourths of
the square (yellow); 5, densely packed cells entirely filling the square
(orange/red).
Additional file 2: Table S1. Dopamine clearance rates in vivo.
Additional file 3: Figure S2. DA clearance parameters measured in
C17.mock and C17.hDAT stem cells transplanted into mouse
cerebral cortex.
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